News

GHO Capital announces two acquisitions to create pan-European ophthalmic specialty pharmaceutical company

5 July 2016 London, UK – GHO Capital, the European specialist investor in healthcare, has entered into an agreement to acquire the European commercial operations of Nicox S.A. (“Nicox”) (Euronext Paris: FR0013018124, COX), the international ophthalmic company, and to acquire the entire issued share capital of Visufarma Spa (“Visufarma”), a private Italian ophthalmic company. The…Read more


Ken Eichmann joins GHO Capital as Principal

29 February 2016 London, UK – GHO Capital, the European specialist healthcare investor, today announces the appointment of Ken Eichmann as Principal. The firm now has a dedicated healthcare team of 10 investment professionals. Ken is an experienced private equity investment professional who brings a wealth of origination, transaction execution and M&A expertise to GHO…Read more


GHO Capital acquires Quotient Clinical

2 December 2015 London, UK – GHO Capital, the European specialist healthcare investor, today announces the acquisition of Quotient Clinical (Quotient or the Company), a provider of outsourced, early-stage drug development services to the pharmaceutical industry. Headquartered in the UK and employing over 280 professionals, Quotient Clinical enables pharmaceutical and biotechnology customers to improve research…Read more


GHO Capital announces acquisition of DNA Diagnostics Center

13 October 2015 London, UK – GHO Capital, the European specialist healthcare investor, today announces the acquisition of DNA Diagnostics Center (DDC or the Company), a world leader in the provision of specialist DNA-based diagnostic services, for a total transaction value of €104 million. Further details of the transaction were not disclosed. DDC is a…Read more


GHO Capital supports European Medicines Agency’s “Science, Medicines, Health: Patients at the heart of future innovation” conference

On Wednesday 18 March 2015, Andrea Ponti, Executive Partner and Founder at GHO Capital, will participate in a panel discussion at the European Medicines Agency’s “Science, Medicines, Health: Patients at the heart of future innovation” conference in London. Andrea will be giving an investor’s view on the regulatory environment in Europe. The invitation-only conference is…Read more